JPWO2022123480A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022123480A5 JPWO2022123480A5 JP2023535631A JP2023535631A JPWO2022123480A5 JP WO2022123480 A5 JPWO2022123480 A5 JP WO2022123480A5 JP 2023535631 A JP2023535631 A JP 2023535631A JP 2023535631 A JP2023535631 A JP 2023535631A JP WO2022123480 A5 JPWO2022123480 A5 JP WO2022123480A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- cancer
- urinary tract
- cellulose
- body cavity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims description 78
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 claims description 49
- 239000000017 hydrogel Substances 0.000 claims description 29
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 24
- 229960004857 mitomycin Drugs 0.000 claims description 24
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 23
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 23
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 23
- 210000001635 urinary tract Anatomy 0.000 claims description 22
- 229920002807 Thiomer Polymers 0.000 claims description 21
- 208000031128 Upper tract urothelial carcinoma Diseases 0.000 claims description 20
- 239000004067 bulking agent Substances 0.000 claims description 19
- 206010028980 Neoplasm Diseases 0.000 claims description 18
- 201000011510 cancer Diseases 0.000 claims description 18
- 239000008194 pharmaceutical composition Substances 0.000 claims description 16
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims description 15
- 239000002202 Polyethylene glycol Substances 0.000 claims description 15
- 229920001223 polyethylene glycol Polymers 0.000 claims description 15
- 208000006593 Urologic Neoplasms Diseases 0.000 claims description 14
- 229920002678 cellulose Polymers 0.000 claims description 12
- 239000001913 cellulose Substances 0.000 claims description 12
- 235000010980 cellulose Nutrition 0.000 claims description 12
- 239000011859 microparticle Substances 0.000 claims description 12
- 206010005003 Bladder cancer Diseases 0.000 claims description 10
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 10
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 10
- 239000004202 carbamide Substances 0.000 claims description 10
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 10
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 claims description 9
- 229920000609 methyl cellulose Polymers 0.000 claims description 9
- 235000010981 methylcellulose Nutrition 0.000 claims description 9
- 239000003795 chemical substances by application Substances 0.000 claims description 8
- 239000001923 methylcellulose Substances 0.000 claims description 7
- 229960002900 methylcellulose Drugs 0.000 claims description 7
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 6
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 6
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 6
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 6
- 229920000639 hydroxypropylmethylcellulose acetate succinate Polymers 0.000 claims description 6
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 claims description 6
- 229920001983 poloxamer Polymers 0.000 claims description 6
- 229960000502 poloxamer Drugs 0.000 claims description 6
- 229940044476 poloxamer 407 Drugs 0.000 claims description 6
- 229920001992 poloxamer 407 Polymers 0.000 claims description 6
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- XNHZZRIKMUCTHU-QTTZVWFDSA-N [(2s,3s)-2,6-diamino-3-hydroxy-7-methyl-5,8-dioxo-2,3-dihydro-1h-pyrrolo[1,2-a]indol-4-yl]methyl carbamate Chemical compound O=C1C(C)=C(N)C(=O)C2=C1N1C[C@H](N)[C@H](O)C1=C2COC(N)=O XNHZZRIKMUCTHU-QTTZVWFDSA-N 0.000 claims description 4
- 230000036760 body temperature Effects 0.000 claims description 4
- 238000012059 flow imaging microscopy Methods 0.000 claims description 4
- 239000003349 gelling agent Substances 0.000 claims description 4
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 3
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical group OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 claims description 3
- 239000001856 Ethyl cellulose Substances 0.000 claims description 3
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 3
- 229920002517 Poloxamer 338 Polymers 0.000 claims description 3
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 3
- 229920002593 Polyethylene Glycol 800 Polymers 0.000 claims description 3
- 229920002125 Sokalan® Polymers 0.000 claims description 3
- ZUAAPNNKRHMPKG-UHFFFAOYSA-N acetic acid;butanedioic acid;methanol;propane-1,2-diol Chemical compound OC.CC(O)=O.CC(O)CO.OC(=O)CCC(O)=O ZUAAPNNKRHMPKG-UHFFFAOYSA-N 0.000 claims description 3
- 235000010443 alginic acid Nutrition 0.000 claims description 3
- 229920000615 alginic acid Polymers 0.000 claims description 3
- 229920013820 alkyl cellulose Polymers 0.000 claims description 3
- 229940053200 antiepileptics fatty acid derivative Drugs 0.000 claims description 3
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 3
- 229920001577 copolymer Polymers 0.000 claims description 3
- 229920001249 ethyl cellulose Polymers 0.000 claims description 3
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 3
- 239000003925 fat Substances 0.000 claims description 3
- 229920013821 hydroxy alkyl cellulose Polymers 0.000 claims description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 3
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 3
- 229940044519 poloxamer 188 Drugs 0.000 claims description 3
- 229920001993 poloxamer 188 Polymers 0.000 claims description 3
- 229920000193 polymethacrylate Polymers 0.000 claims description 3
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 claims 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims 1
- 229940072056 alginate Drugs 0.000 claims 1
- 229960001631 carbomer Drugs 0.000 claims 1
- 239000001768 carboxy methyl cellulose Substances 0.000 claims 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims 1
- 229940105329 carboxymethylcellulose Drugs 0.000 claims 1
- 230000003232 mucoadhesive effect Effects 0.000 description 17
- 238000000034 method Methods 0.000 description 12
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063124111P | 2020-12-11 | 2020-12-11 | |
| US63/124,111 | 2020-12-11 | ||
| PCT/IB2021/061499 WO2022123480A1 (en) | 2020-12-11 | 2021-12-09 | Material and method for treating cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023553976A JP2023553976A (ja) | 2023-12-26 |
| JP2023553976A5 JP2023553976A5 (https=) | 2024-12-13 |
| JPWO2022123480A5 true JPWO2022123480A5 (https=) | 2024-12-13 |
Family
ID=78916713
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023535631A Pending JP2023553976A (ja) | 2020-12-11 | 2021-12-09 | がんを治療するための材料及び方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US12336979B2 (https=) |
| EP (1) | EP4259093B1 (https=) |
| JP (1) | JP2023553976A (https=) |
| KR (1) | KR20230118632A (https=) |
| CA (1) | CA3201129A1 (https=) |
| WO (1) | WO2022123480A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10471150B2 (en) | 2010-01-20 | 2019-11-12 | Urogen Pharma Ltd. | Material and method for treating internal cavities |
| US12336979B2 (en) | 2020-12-11 | 2025-06-24 | Urogen Pharma Ltd. | Material and method for treating cancer |
| US20240100019A1 (en) * | 2022-09-28 | 2024-03-28 | Urogen Pharma Ltd. | Compositions comprising a thermoreversible hydrogel, and having an extended in-use period |
| EP4713013A1 (en) | 2023-05-16 | 2026-03-25 | UroGen Pharma Ltd. | Immunomodulating treatments of body cavities |
| KR20260043121A (ko) | 2023-07-25 | 2026-03-31 | 우로젠 파마 엘티디. | 미토마이신을 함유하는 열 겔화 제약 조성물을 사용한 저등급 중간-위험 비근침습성 방광암의 치료 |
| CN121729785A (zh) | 2023-09-06 | 2026-03-24 | 株式会社Lg新能源 | 袋用片材、袋型电池盒以及用于制造电池盒的方法 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0386960A3 (en) | 1989-03-07 | 1991-10-23 | American Cyanamid Company | Pharmaceutical compositions useful as drug delivery vehicles and/or as wound dressings |
| US5861174A (en) | 1996-07-12 | 1999-01-19 | University Technology Corporation | Temperature sensitive gel for sustained delivery of protein drugs |
| US6286513B1 (en) | 1998-10-22 | 2001-09-11 | Jessie L. Au | Methods for treating superficial bladder carcinoma |
| US20040009212A1 (en) | 2002-01-30 | 2004-01-15 | Pharma Power Biotec Co. Ltd. | Mucoadhesive thermoresponsive medicament-carrier composition |
| GB0328060D0 (en) | 2003-12-04 | 2004-01-07 | Sod Conseils Rech Applic | Botulinum toxin treatment |
| GB0414825D0 (en) | 2004-07-02 | 2004-08-04 | Biostatus Ltd | Gel formulations and uses thereof |
| US20090142259A1 (en) | 2006-05-12 | 2009-06-04 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of bladder and urinary tract tumors |
| US9107815B2 (en) | 2008-02-22 | 2015-08-18 | Allergan, Inc. | Sustained release poloxamer containing pharmaceutical compositions |
| EP2313122B1 (en) | 2008-07-17 | 2019-03-06 | Micell Technologies, Inc. | Drug delivery medical device |
| US10471150B2 (en) | 2010-01-20 | 2019-11-12 | Urogen Pharma Ltd. | Material and method for treating internal cavities |
| ES2732150T3 (es) * | 2010-01-20 | 2019-11-20 | Urogen Pharma Ltd | Material y método para tratar cavidades internas |
| EP2734187B1 (en) * | 2011-07-20 | 2018-09-05 | UroGen Pharma Ltd. | Materials and method for treating internal body cavities |
| US20140142191A1 (en) | 2011-07-20 | 2014-05-22 | Theracoat Ltd. | Production of thermoreversible hydrogels for therapeutic applications |
| PT2865391T (pt) * | 2013-10-22 | 2017-12-22 | Medac Ges Für Klinische Spezialpräparate Mbh | Processo para a produção de uma composição farmacêutica liofilizada com um conteúdo de mitomicina c |
| US9801854B1 (en) * | 2014-01-17 | 2017-10-31 | Urogen Pharma Ltd. | Slow release formulations of cell cycle regulators and anti-cancer agents for local treatment of solid cancer |
| WO2016004213A2 (en) | 2014-07-01 | 2016-01-07 | Vicus Therapeutics, Llc | Hydrogels for treating and ameliorating cancers and potentiating the immune system and methods of making and using them |
| US20170128424A1 (en) | 2015-11-11 | 2017-05-11 | Qrono, Inc. | Sustained release pharmaceutical compositions and methods of use |
| JP7265989B2 (ja) * | 2016-10-25 | 2023-04-27 | ウロゲン ファーマ リミテッド | 体腔の免疫調節治療 |
| WO2018169960A1 (en) | 2017-03-17 | 2018-09-20 | The Johns Hopkins University | Nanoparticle formulations for enhanced drug delivery to the bladder |
| EP3498270A1 (en) * | 2017-10-30 | 2019-06-19 | Urogen Pharma Ltd. | Slow release formulations of cell cycle regulators and anti-cancer agents for local treatment of solid cancer |
| US12336979B2 (en) | 2020-12-11 | 2025-06-24 | Urogen Pharma Ltd. | Material and method for treating cancer |
-
2021
- 2021-12-09 US US17/546,204 patent/US12336979B2/en active Active
- 2021-12-09 EP EP21824683.3A patent/EP4259093B1/en active Active
- 2021-12-09 JP JP2023535631A patent/JP2023553976A/ja active Pending
- 2021-12-09 WO PCT/IB2021/061499 patent/WO2022123480A1/en not_active Ceased
- 2021-12-09 KR KR1020237023151A patent/KR20230118632A/ko active Pending
- 2021-12-09 CA CA3201129A patent/CA3201129A1/en active Pending
-
2023
- 2023-12-11 US US18/535,108 patent/US12171747B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103118662B (zh) | 制备冻干速溶多相剂型的方法 | |
| JP2010532746A (ja) | 放出調節医薬組成物およびその製造方法 | |
| JP7091477B2 (ja) | エダラボン医薬組成物 | |
| CN101636152A (zh) | 含有西洛他唑的控释制剂及其制备方法 | |
| EP4259093B1 (en) | Material and method for treating cancer | |
| WO2009048698A4 (en) | Co-solvent compositions and methods for improved delivery of dantrolene therapeutic agents | |
| CN101631533B (zh) | 含有西洛他唑的控释制剂及其制备方法 | |
| CN1398184A (zh) | 具有改善的生物利用度和缩小的个体内和个体间吸收差异的含有伊曲康唑的组合物 | |
| EP3146962A1 (en) | Allisartan isoproxil solid dispersion and pharmaceutical composition thereof | |
| TWI592154B (zh) | Allisartan-based solid dispersions and pharmaceutical compositions containing the solid dispersions | |
| JPWO2022123480A5 (https=) | ||
| JPWO2021138483A5 (https=) | ||
| CN101011393B (zh) | 厄贝沙坦胃内滞留型缓释药物组合物 | |
| WO2012013116A1 (zh) | 含氨基酸稳定剂的替莫唑胺药物组合物及其制备方法 | |
| JP2011521942A (ja) | ユーフォルビア・プロストラータを含有する組成物およびその調製方法 | |
| CN107072954B (zh) | 用于口服给药的包含洛贝格列酮的药物组合物 | |
| KR101068475B1 (ko) | 실로스타졸을 포함하는 서방성 제제 및 이의 제조방법 | |
| WO2016121147A1 (ja) | 注腸剤 | |
| JP7396598B2 (ja) | 皮膚創傷用組成物 | |
| KR102306856B1 (ko) | 용출률 및 경구 흡수율이 개선된 셀레콕시브 고체 분산체 및 이의 제조방법 | |
| CN114533690A (zh) | 含抗凝血药物西洛他唑的新制剂及其制备方法 | |
| KR102752715B1 (ko) | 두타스테리드 및 타다라필을 포함하는 복합제제 및 이의 제조방법 | |
| CN102144979B (zh) | 用于治疗肿瘤的左旋棉酚或其醋酸盐的注射用冻干粉制剂 | |
| WO2025252204A1 (en) | Amorphous solid dispersions of a braf inhibitor | |
| WO2025026423A1 (en) | Compositions, their use and manufacture for treatment of gastrointestinal conditions |